Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Seagen Inc. (SGEN)

197.64   -0.46 (-0.23%) 03-24 16:00
Open: 198.1 Pre. Close: 198.1
High: 198.295 Low: 196.96
Volume: 767,301 Market Cap: 36,981(M)

Technical analysis

as of: 2023-03-24 4:29:45 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 236.94     One year: 276.74
Support: Support1: 173.12    Support2: 154.75
Resistance: Resistance1: 202.86    Resistance2: 236.94
Pivot: 191.33
Moving Average: MA(5): 198.88     MA(20): 188.3
MA(100): 144.14     MA(250): 148.21
MACD: MACD(12,26): 11.8     Signal(9): 12.3
Stochastic oscillator: %K(14,3): 85.7     %D(3): 87.9
RSI: RSI(14): 74.8
52-week: High: 202.86  Low: 105.43
Average Vol(K): 3-Month: 1,350 (K)  10-Days: 2,216 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SGEN ] has closed below upper band by 36.1%. Bollinger Bands are 102.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 25 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 198.59 - 199.98 199.98 - 201.05
Low: 193.26 - 195.18 195.18 - 196.65
Close: 195.01 - 197.58 197.58 - 199.56

Company Description

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Headline News

Fri, 24 Mar 2023
Guru Fundamental Report for SGEN - Nasdaq

Thu, 23 Mar 2023
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors ... - InvestorsObserver

Thu, 23 Mar 2023
Seagen Inc. (NASDAQ:SGEN) Shares Sold by Gateway Investment ... - MarketBeat

Thu, 16 Mar 2023
Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be ... - Nasdaq

Wed, 15 Mar 2023
Seagen Inc. (NASDAQ:SGEN) Shares Sold by Seaport Global ... - MarketBeat

Tue, 14 Mar 2023
STOCKHOLDER ALERT: The M&A Class Action Firm Announces ... - PR Newswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 186 (M)
Shares Float 137 (M)
% Held by Insiders 0.9 (%)
% Held by Institutions 90.9 (%)
Shares Short 3,000 (K)
Shares Short P.Month 2,710 (K)

Stock Financials

EPS 3.57
EPS Est Next Qtl -0.42
EPS Est This Year -1.7
EPS Est Next Year -1.24
Book Value (p.s.) 18.88
Profit Margin (%) -34.2
Operating Margin (%) -33.9
Return on Assets (ttm) -10.4
Return on Equity (ttm) -21.3
Qtrly Rev. Growth 20.2
Gross Profit (p.s.) 0.18
Sales Per Share 10.01
EBITDA (p.s.) -3.03
Qtrly Earnings Growth 0
Operating Cash Flow -658 (M)
Levered Free Cash Flow -454 (M)

Stock Valuations

PE Ratio 55.2
PEG Ratio 0.3
Price to Book value 10.46
Price to Sales 19.72
Price to Cash Flow -55.8

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.